4D Molecular Therapeutics (FDMT) Capital Expenditures: 2020-2025
Historic Capital Expenditures for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$91,000.
- 4D Molecular Therapeutics' Capital Expenditures fell 105.12% to -$91,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 54.08%. This contributed to the annual value of $3.8 million for FY2024, which is 36.63% up from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Capital Expenditures is -$91,000, which was down 237.88% from $66,000 recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Capital Expenditures registered a high of $6.4 million during Q1 2022, and its lowest value of -$91,000 during Q3 2025.
- Moreover, its 3-year median value for Capital Expenditures was $631,000 (2025), whereas its average is $651,182.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Capital Expenditures spiked by 944.26% in 2021, and later plummeted by 105.12% in 2025.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Capital Expenditures stood at $5.1 million in 2021, then crashed by 78.55% to $1.1 million in 2022, then tumbled by 49.77% to $549,000 in 2023, then spiked by 72.86% to $949,000 in 2024, then slumped by 105.12% to -$91,000 in 2025.
- Its Capital Expenditures was -$91,000 in Q3 2025, compared to $66,000 in Q2 2025 and $631,000 in Q1 2025.